Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-016536
Filing Date
2019-05-07
Accepted
2019-05-07 16:23:49
Documents
53
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fate-10q_20190331.htm 10-Q 1555933
2 EX-31.1 fate-ex311_7.htm EX-31.1 9827
3 EX-32.1 fate-ex321_9.htm EX-32.1 4809
  Complete submission text file 0001564590-19-016536.txt   6408016

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT fate-20190331.xml EX-101.INS 1420714
5 XBRL TAXONOMY EXTENSION SCHEMA fate-20190331.xsd EX-101.SCH 53495
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20190331_cal.xml EX-101.CAL 50571
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20190331_def.xml EX-101.DEF 184581
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20190331_lab.xml EX-101.LAB 430108
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20190331_pre.xml EX-101.PRE 313726
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 19803455
SIC: 2836 Biological Products, (No Diagnostic Substances)